FDL169 a CFTR Corrector

FDL169 Phase 1b Study

FDL169-2016-04 Study is a randomized, double-blind, placebo-controlled, parallel study to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FDL169 in cystic
fibrosis subjects homozygous for the F508del-CFTR mutation.

Enrollment is planned to occur at approximately 14 global sites. Approximately 24 adults with CF will be enrolled in the study. Participation in this study will take approximately 9 weeks.

**Requirements for participation in the study:**

- A diagnosis of cystic fibrosis
- Have 2 copies of the F508del-CFTR mutation
- Be 18 years of age or older
- Have a weight ≥40 kg
- Have an FEV1 ≥ 40% predicted
- No respiratory tract infection, pulmonary exacerbation, or changes in therapy for pulmonary disease 4 weeks prior to dosing
- No treatment with ivacaftor or lumacaftor 4 weeks prior to dosing

Additional information is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov)
We’d love to hear it!